Biogen Ma Inc.

Thomas O Cameron

Justin Andrew Caravella

Kenneth J Simon

Mia Marie Rushe

Joseph Arndt

R Blake Pepinsky

Deping Wang

Ellen Garber Stark

Karl J M Hanf

Isin Dalkilic-Liddle

Nadia Giselle D'lima

Eric Day

Karl John Mortley Hanf

Ellen Duggan Cahir-mcfarland

George Campbell Kaynor

Fang Qian

Benjamin A Smith

Janine Lisa Ferrant-orgettas

Robert Blake Pepinsky

The invention relates to anti-VLA-4 antibodies and binding fragments thereof. The invention further includes polynucleotides encoding said antibodies and binding fragments thereof and methods of manufacturing said antibodies and binding fragments thereof. The invention further includes methods of treating patients suffering from multiple sclerosis and/or epilepsy by administration of said antibodies and binding fragments thereof. The invention further includes methods of reducing the susceptibility to scrambling of a recombinant anti-alpha 4 antibody or a binding fragment thereof.

Anti-VLA-4 antibodies having reduced effector function

The present disclosure provides anti-transferrin receptor antibodies, compositions comprising the same and methods of their use. This disclosure also provides polynucleotides and vectors encoding the anti-transferrin receptor antibodies and cells comprising the same, methods of making the antibodies, and molecules comprising the antibodies.

Anti-transferrin receptor antibodies and uses thereof

In one aspect, the disclosure provides neutralizing antibodies against JCV and methods for the treatment of PML. In some embodiments, aspects of the invention relate to an isolated JC-virus neutralizing monoclonal antibody against JCV capsid protein VPI (JCV-VP1). In some embodiments, the antibody suppresses infectivity of the JC-virus. In some embodiments, the antibody binds the sialic acid binding pocket of JCV-VPI. In some embodiments, the antibody binds JCV-VP 1 comprising one or more of the following mutations: S269F, S269Y, S267F, N265D, Q271 H, D66H, K60E, K60N and L55F.

JCV neutralizing antibodies

In one aspect, the disclosure provides neutralizing antibodies against JCV and methods for the treatment of PML. In some embodiments, aspects of the invention relate to an isolated JC-vims neutralizing monoclonal antibody against JCV capsid protein VPI (JCV-VP1). In some embodiments, the antibody suppresses infectivity of the JC-vims. In some embodiments, the antibody binds the sialic acid binding pocket of JCV-VP1.

Growing community of inventors

Cambridge, MA, United States of America

Thomas O Cameron